The senate passed new legislation that would empower the FDA to monitor the safety and efficacy of drugs already on the market.  Currently the FDA’s oversight is primarily limited primarily to pre-market approval, including the so-called clinical trial process.  Of particular interest is that under this plan the FDA would systematically track adverse drug reactions, the cause of up to 100,000 deaths annually in the United States.

Original Article